Oral semaglutide 25 mg in adults with overweight or obesity
New England Journal of Medicine
2025
Study summary
Oral semaglutide 25 mg was studied for weight management in adults with overweight or obesity.
Peptides studied
Goals studied
Stack studied
Metabolic Stack
Key findings
Oral semaglutide 25 mg led to greater mean weight reduction than placebo.
Study details
Study type
randomized clinical trial
Journal
New England Journal of Medicine
DOI / PubMed
10.1056/NEJMoa2403347
Year
2025
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.
